{"entity":{"id":"bioinvent-international","kind":"company","name":"BioInvent International","aka":["BioInvent International AB"],"tldr":"BioInvent International is a Sweden-based biotechnology company running 4 late-stage cancer trials of BI-1607, Ipilimumab (YervoyTM and BI-1910 in melanoma, uveal melanoma and non-small-cell lung cancer.","summary":"BioInvent International, based in Lund, Sweden, is a biotechnology company. BioInvent International is a clinical-stage company that discovers and develops antibodies for cancer immunotherapy, using its proprietary F.I.R.S.T. platform and n-CoDeR antibody library. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing BI-1607, Ipilimumab (YervoyTM, BI-1910, BI1206 and BI-1808 in melanoma, uveal melanoma, non-small-cell lung cancer, hepatocellular carcinoma and ovarian cancer. The largest, NCT04219254 (A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours), plans to enrol 197 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Bioinvent","links":[{"label":"Official website","url":"https://www.bioinvent.com"},{"label":"ClinicalTrials.gov: trials led by BioInvent International","url":"https://clinicaltrials.gov/search?lead=BioInvent%20International%20AB"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","uveal-melanoma","nsclc","hcc","ovarian","peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04752826","nct06784648","nct06205706","nct04219254"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Lund","country":"SE","companyType":"biotech","website":"https://www.bioinvent.com","stage":"public","investors":[],"funding":[]},"route":"/companies/bioinvent-international/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"trial":[{"id":"nct04219254","kind":"trial","name":"A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","route":"/trials/nct04219254/"},{"id":"nct04752826","kind":"trial","name":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","route":"/trials/nct04752826/"},{"id":"nct06205706","kind":"trial","name":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors","route":"/trials/nct06205706/"},{"id":"nct06784648","kind":"trial","name":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","route":"/trials/nct06784648/"}]}}